Valeant Pharmaceuticals (VRX) Announces Increase in Stock Buyback Authorization
More News related to VRX
- Matrix USA Rating Changes 10/2
- Lazard Upgrades Valeant Pharma (VRX) to Hold
- DFB Sells Coria Labs to Valeant Pharmaceuticals
- Valeant Pharmaceuticals (VRX) Agrees to Acquire Coria Labs for $95M
- Valeant Pharmaceuticals Signs Agreement to Acquire Coria Laboratories, Ltd.
More News related to Stock Buybacks
- W. P. Carey & Co. (WPC) Authorizes the Repurchase of up to $10 Million in Common Stock
- Mid Penn Bancorp (MPB) Approves 50K Share Buyback
- Global-Tech Appliances (GAI) Announces $2M Stock Buy Back
- Linn Energy (LINE) Announces $100M Buyback
Valeant Pharmaceuticals (NYSE: VRX) announced that its board has authorized the repurchase of an additional $100 million of its outstanding common stock under its 2007 stock repurchase program. This repurchase authorization raises the aggregate repurchase authorization to $300 million from the $200 million over a period of 24 months previously approved by the board on June 7, 2007. The repurchase program is designed to increase shareholder value and reflects the company's confidence in the long-term value of its common stock.
Valeant Pharmaceuticals International (NYSE: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology and dermatology.
Sign up at EasyStockAlerts.com To Be Alerted To Your Stock News!
Related Categories
Stock BuybacksStocks Mentioned
-0.68Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
